No Data
Longshen Rongfa: 2024 Annual Report Summary
Longshen Rongfa: 2024 Annual Report
Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ) released its performance for the year 2024, with a net income of 25.8046 million yuan, a decrease of 58.14%.
Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ) released its 2024 annual report, with the company revenue at 1.039 billion...
Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ): plans to purchase 70% equity of the research institute for 8.58494 million yuan.
On March 24th, Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ) announced that the company intends to purchase 70% of the shares of Gansu Pharmaceutical Group's Technology Innovation Research Institute (hereinafter referred to as "the Research Institute" or "the symbol company") held by Gansu Pharmaceutical Investment Group Co., Ltd. (hereinafter referred to as "Gansu Pharmaceutical Group") in cash, with a transaction price of 8.58494 million yuan. Upon completion of this transaction, the company will hold 70% of the shares of the Research Institute, which will become a controlling subsidiary of the company.
Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ): Sanyuan Pharmaceutical has obtained the renewed "medical instruments Operation License."
On March 19, Gelonghui reported that Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ) announced that its wholly-owned subsidiary Gansu Pharmaceutical Group Sanyuan Medical Co., Ltd. (referred to as "Sanyuan Medical") recently received a new "Medical Instruments Operation License" reissued by the Lanzhou Market Supervision Administration due to changes in its legal representative and business leader.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Some Confidence Is Lacking In Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (SZSE:300534) As Shares Slide 32%
